Genmab — April 2016
-
det kan vist ikke betale sig at skuffe forventninger i det her marked....
-
IMGN justerede guidance - 2016 guidance for its net loss is now expected to be between $135 million and $140 million, versus previous estimate of $120 million and $125 million
-
så ikke noget med klinikken
-
hold da helt kæft, hvor er US sur!
-
kan det anbefales at købe genmab aktier nu?
-
hmm - US minder mest om en basejumper, der har glemt dragten
-
Genmab er stadig det store hit hos Investtec. http://penge.borsen.dk/artikel/1/323780/teknisk_analyse_potentiale_paa_24_pct_i_neutralt_marked.html
-
på mb er de forundret over at castor ikke har fået mere bevågenhed. For de informationer som genmab er kommet med, er uden fortilfældehttps://www.google.dk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjf0MLB37TMAhXrE5oKHWTPBzMQFggdMAA&url=http%3A%2F%2Fwww.myelomabeacon.com%2Fdeutsch%2F2016%2F04%2F29%2Fmyeloma-morning-darzalex-castor-treanda-stammzelltransplantation%2F&usg=AFQjCNGaKsEwCGz8gH9xce5L1wIDLGOCBw&bvm=bv.121070826,d.bGs
-
God morgen.

-
Velkommen til Thy Niko og andreas961.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind